EQUITY RESEARCH MEMO

Niya Biotech

Generated 5/25/2026

Executive Summary

Conviction (model self-assessment)50/100

Niya Biotech, a division of Albia Biocare, is a PCD pharma franchise company headquartered in Jalandhar, Punjab, India, established in 2019. It offers a comprehensive portfolio of herbal and allopathic pharmaceutical products across more than 12 therapeutic categories, including analgesics, gastroenterology, antibiotics, and dermatology. The company manufactures in GMP/WHO-certified facilities and provides franchise partners with monopoly rights, technical support, and promotional assistance. With a focus on affordable, high-quality dosage forms such as tablets, capsules, and injectables, Niya Biotech has positioned itself as a reliable partner in the Indian pharmaceutical franchise market. The company operates at a commercial stage with an employee base of 50–200 and aims to expand its reach through its franchise model.

Upcoming Catalysts (preview)

  • Q3 2026Expansion of product portfolio into new therapeutic categories60% success
  • Q4 2026Onboarding of new franchise partners in underpenetrated regions70% success
  • TBDObtaining additional regulatory certifications (e.g., ISO or WHO-GMP) for manufacturing facilities80% success
Locked sections
  • · Pipeline Analysis
  • · Competitive Landscape
  • · Catalyst Calendar (full 12-month)
  • · Bull Case
  • · Bear Case
  • · Counterfactual Scenarios
  • · Valuation Notes
  • · SEC Filing Highlights
  • · Insider Activity
  • · Literature Watch
  • · Patent Landscape
  • · Mechanism Cluster Map
  • · Audio Briefing (5 min)